The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2024 | Managing adverse events associated with BTKis when treating patients with MCL
Michael Wang, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the management of cardiac adverse events associated with BTK inhibitors (BTKis) when treating patients with mantle cell lymphoma (MCL). He emphasizes the importance of working closely with cardiologists and monitoring patients for toxicities. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
